Revelation Biosciences Inc (REVB)
2.20
-0.03
(-1.35%)
USD |
NASDAQ |
May 09, 16:00
2.19
-0.01
(-0.45%)
After-Hours: 20:00
Revelation Biosciences Cash from Operations (TTM): -7.286M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -7.286M |
| September 30, 2023 | -6.231M |
| June 30, 2023 | -6.246M |
| March 31, 2023 | -7.964M |
| December 31, 2022 | -11.22M |
| Date | Value |
|---|---|
| September 30, 2022 | -13.15M |
| June 30, 2022 | -13.65M |
| March 31, 2022 | -13.54M |
| December 31, 2021 | -11.09M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-13.65M
Minimum
Jun 2022
-6.231M
Maximum
Sep 2023
-10.04M
Average
-11.09M
Median
Dec 2021
Cash from Operations (TTM) Benchmarks
| Cardiff Oncology Inc | -29.97M |
| Ocular Therapeutix Inc | -70.23M |
| Ocugen Inc | -62.05M |
| Cue Biopharma Inc | -39.96M |
| Solid Biosciences Inc | -94.18M |